Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Research Discovers New Compounds Active Against Tuberculosis and Malaria

By Drug Discovery Trends Editor | January 22, 2008

Esther Vicente, PhD, a chemistry researcher at the University of Navarra, has discovered new compounds active for treating tuberculosis and malaria. Her thesis, defended at the Faculty of Sciences in Pamplona, describes the synthesis and characterization of 65 derivatives of quinoxaline, the structure of which is similar to a number of antimalalarial and antituberculosis pharmaceutical drugs currently on the market. Of the molecules prepared, four stand out for their antimalalarial activity and 15 for their antituberculosis activity.

The synthesis and characterization of the new compounds was undertaken at the Centro de Investigación de Farmacobiología Aplicada (CIFA) of the University of Navarra. Esther Vicente did research for five months at the London School of Hygiene and Tropical Medicine in the UK, where she drew up the evaluation of the antimalarial activity of her products. The antituberculosis work was carried out at the Southern Research Institute of Birmingham, within the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) that is subsidised by the National Institute of Allergy and Infectious Diseases in Bethesda.

Release date: January 22, 2008
Source: Basque Research


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE